A Study of LY4178256 in Healthy Participants

Part of paid clinical trials in Los Alamitos, California.

Sponsor
Eli Lilly and Company
Study ID
NCT07698210
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • LY4178256 — DRUG
    Administered intravenously (IV)
  • Placebo — DRUG
    Administered IV

Study Details

The main purpose of this study is to evaluate how well LY4178256 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to check how much LY4178256 gets into the bloodstream and how long it takes the body to eliminate it. For each participant, the study will last about 7 months and will include either 7 or 12 visits depending on the assigned treatment.

Key Dates

First listed
Jul 13, 2026
Start date
Jul 31, 2026
Status verified
Jul 2026
Primary completion
Feb 29, 2028
Completion
Feb 29, 2028

Study Design

Enrollment
88 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4178256 Part A: Single-Ascending Dose (SAD) (Cohorts 1-6b)
    LY4178256 or Placebo administered Intravenously (IV)
  • Experimental: LY4178256 Part B: Multiple Ascending Dose (MAD) (Cohorts 1-3)
    LY4178256 or Placebo administered IV

Primary Outcome Measure

Part A: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. [ Time Frame: Screening to Day 169 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (2)

FacilityCityStateZIPSite coordinators
Collaborative Neuroscience Network - CNSLos AlamitosCalifornia90720
844-424-9494
Steven Reynolds (PRINCIPAL_INVESTIGATOR)
ICONSalt Lake CityUtah84124
801-904-4600
Ahad Sabet (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Alamitos, CA

By research site
Collaborative Neuroscience Network - CNS· Los Alamitos, CAICON· Salt Lake City, UT

Related Studies